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Abstract
Background: It is known that sensitivity or resistance of tumor cells to a given chemotherapeutic
agent is an acquired characteristic(s), depending on the heterogeneity of the tumor mass subjected
to the treatment. The clinical success of a chemotherapeutic regimen depends on the ratio of
sensitive to resistant cell populations.
Results: Based on findings from clinical and experimental studies, a unifying model is proposed to
delineate the potential mechanism by which tumor cells progress towards multi drug resistance,
resulting in failure of chemotherapy.
Conclusion: It is suggested that the evolution of multi drug resistance is a developmentally
orchestrated event. Identifying stage-specific time windows during this process would help to
identify valid therapeutic targets for the effective elimination of malignancy.
Background
The phenomenon of drug resistance is a distinct and mul-
tifactorial entity culminating in the failure of therapeutic
regimens in clinical oncology. From the clinical perspec-
tive, the emergence of drug resistance is determined by the
rate of tumor growth, in conjunction with the remission
index subsequent to chemotherapy. In contrast, experi-
mental model(s) for studying drug resistance involve
either homogeneous cell populations or co-culture mod-
els where the time frame ranges from a few days to a week
at the most. It is obvious that the biochemical and collec-
tive physiological process that coexist in the cancer patient
are totally distinct and do not warrant direct comparison
with experimental data.
A tumor mass encompassing approximately 1011 to 1012
cells is considered a lethal tumor burden. Depending on
the sensitivity of a given tumor cell population to anti-
neoplastic drug(s) (chemotherapeutic agents), and the
dose administered, the effectiveness of the therapy,
referred to as "Cell Kill", is determined. "Cell Kill"
depends on the inherent susceptibility of the tumor bur-
den. The "Cell Kill" of a given tumor burden varies
between 90 % to 99.99%. If we assume that, under the
best therapeutic regimen, one round of chemotherapy or
radiation therapy would be likely to achieve a 99.99%
"cell kill" in a tumor burden of 1011cells, this would
reduce the tumor burden to 108 cells. It should be noted
that chemotherapy and radiation therapy exert considera-
ble toxic effects on normal cells; because of this factor, the
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treatment regimen is staged in cycles. It is reasonable to
presume that both the normal cells and the less sensitive
tumor cells would be likely to proliferate with one or
more defects after each cycle of the therapy.
Even if the most fortunate circumstances were to prevail
for early detection followed by treatment, the size of the
"tumor burden", the sensitivity of the tumor cells and the
effectiveness of the therapy ("Cell kill") remain decisive in
determining the outcome of the therapy. Clinical observa-
tion shows that relapse or recurrence of the tumor is
always a possibility. This is partly due to the fact that diag-
nostic procedures are inadequate for detecting as few as
106 or 108 tumor cells in cancer patients. This technical
shortcoming confers a growth advantage on both unde-
tectable and insensitive tumor cells. Under these circum-
stances, should there be a relapse, the tumor burden
would probably be composed of a heterogeneous popula-
tion of tumor cells. These include both drug sensitive and
drug resistant cells in either proliferating or dormant
states. According to Gompertzian Kinetics, as the tumor
burden increases, the number of proliferating cells would
decrease. Also, it is known that in a given tumor burden,
a considerable number of cells are in the resting phase;
these are not sensitive to chemotherapy or radiation ther-
apy [1].
As a result it would require a much higher dose of chem-
otherapeutic drugs or radiation therapy to achieve the
maximal "Cell Kill" in a given tumor burden. It is known
that higher drug doses are often correlated with increased
response rates in terms of the effective and maximal "Cell
Kill", thus offering a window of opportunity for cure
(complete remission). However, there is no assurance that
complete remission would be the immediate outcome
after a given therapeutic regimen. It is known that the
effectiveness of an anti-neoplastic drug depends on i) the
half life of the drug in vivo, ii) the rate and iii) amount of
the drug being absorbed (bioavailability), and iv) the tox-
icities of biologically active metabolites of the drug [2-4].
The biologically active form of a drug, and the effective
range of radiation therapy, are not uniformly distributed,
so the entire tumor burden is not reached. Therefore, in a
given tumor burden, the entire cell population is not
exposed to effective therapy, leaving a finite region insuf-
ficiently exposed to the drug or its biologically active
metabolite(s). Considering these factors in the context of
ongoing therapy, it is common practice to re-evaluate
patients after 2 or 3 cycles of chemotherapy to determine
its effectiveness. Depending on the toxicity profile and the
rate of tumor progression versus "Cell Kill", either the
therapy is continued or multiple drugs are used to achieve
maximal "Cell Kill" to obtain complete remission.
Here, I advance a hypothesis for multi drug resistance
based on the aforementioned factors: the ETP model. The
founding factors are: 1. The sigmoidal curve depicting the
toxicity-dose relationship for a given chemotherapeutic
drug indicates that lower doses give lower toxicity but less
"Cell Kill", whereas an increased dose would increase the
toxicity with a better "Cell Kill" [5,6]. However the opti-
mal dose required for a given therapeutic compound to
achieve a maximal "Cell Kill" for a particular malignancy
with minimum cytotoxicity is not well defined. This paves
the way for cells within the tumor burden to acquire and
evolve one or more mechanism(s) for survival under the
drug-induced toxic environment during and after treat-
ment. Therefore, it follows that the surviving tumor cells
in a given "tumor burden" should be viewed as the best-
suited or best-adapted for withstanding these toxic effects
as a result of acquiring a relevant genotype and/or pheno-
type conferring "multi drug resistance" [7,8].
2.  In terms of experimental data, I have consistently
observed that periodic exposure to alkylating agents is a
principal requirement for retaining the drug-resistance
property of the drug-resistant variant of human ovarian
carcinoma compared to the drug-sensitive tumor cells in
vitro. If no drug treatment were provided, would the drug-
resistant variant revert to a sensitive phenotype and subse-
quently die? Absence of drug exposure of resistant cells
indeed causes reversion to a drug sensitive phenotype,
which is intriguing as it implies that drug resistance is a
transient phenomenon not an everlasting property, at
least in vitro. Also, as the selection pressure is maintained
with periodic drug treatment, the doubling rate of the
drug resistant cells decreases compared to the drug-sensi-
tive phenotype (Figure 1). Obviously, a considerable dif-
ference in biochemical properties between these two cell
lines is to be expected; however, this is not the case (Kan-
nan,  Unpublished observations). On the contrary, if
chemotherapeutic or radiation therapy is discontinued,
relapse with or without an aggressive increase in tumor
burden is observed in a cancer patient.
Absence of therapy does not result in a complete remis-
sion paralleling the complete reversion to drug sensitivity
that is observed in vitro. The phenomenon is rare, indeed
scarcely possible, in the clinical scenario. As such, there is
no direct correlation between clinical case reports and
experimental data. This contradiction warrants critical
appraisal of the published literature, which is seminal and
has exerted a profound impact on our understanding of
the most complex and still unattainable goal of complete
recovery in any given cancer treatment. Based on extensive
analysis of the published literature and experimental evi-
dence, I propose a model to account for the incongruity or
discrepancy between the experimental and clinical drug
resistance data.Theoretical Biology and Medical Modelling 2005, 2:17 http://www.tbiomed.com/content/2/1/17
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Although the biochemical basis of drug resistance has
been extensively studied in both in vitro model systems
and clinical specimens, no correlation has been forthcom-
ing. Considering the disparity between experimental and
clinical findings, it is clear that we currently lack an under-
standing of the physiological basis of the evolution of
drug-resistant cells. The expression of proteins that play a
pivotal role in cellular drug resistance, such as P-glycopro-
tein, MRP-1 and other members of the ATP-binding cas-
sette family of efflux protein(s), has been shown to
decline at the time of relapse compared to the initial pres-
entation of a given type of cancer. However, this observa-
tion has not been corroborated in all types of cancer.
MRP-1 mediated drug efflux has been shown to correlate
with an elevated level of intracellular glutathione (GSH),
GSH synthesis or glutathione S-transferase (GST) activity.
GST-mediated glutathionyl S-conjugates are known to be
removed from the intracellular milieu by an energy-
dependent process, similar to that seen with MRP-1,
which is mediated by ATP-binding cassette proteins. It is
known that GST is expressed in four different isoforms (α ,
, π ,  ) but it has not yet been confirmed that expression
of GST-π  confers drug resistance or whether this isoform
is present in drug-resistant cells [9].
Among the properties that differentiate tumor cells from
normal cells are the presence of growth factors potentiat-
ing vascular growth, highly heterogeneous oxygen tension
distributions, extreme acidic or alkaline pH, higher rates
of glucose delivery and utilization, and finally, a state of
hypoxia with an acidotic environment that is noncycling.
This, in turn, endows the cell population with a lack of
Schematic representation of an experimental drug resistance model Figure 1
Schematic representation of an experimental drug resistance model.
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uniform sensitivity to different families of
chemotherapeutic drugs. Oxidative stress has been dem-
onstrated to induce genomic instability at a much higher
rate than is seen in drug-sensitive cells. All these factors
contribute to the development of drug resistance [10].
In addition, drug-resistant cells have evolved mechanisms
for bypassing apoptosis (the controlled form of cell death
due to dehydration, shrinkage, and fragmentation of the
nucleus, eventually leading to phagocytosis by macro-
phages) and necrosis (a traumatic but passive form of cell
death due to the dysfunction of ion-transporting proteins,
cell swelling and lysis and associated with the release of
inflammatory mediators) [11].
Rationale
Therefore, it is hypothesized that the formation of drug-
resistant tumor cells occurs in at least two distinct stages,
namely physiological drug resistance and pathological
drug resistance. Physiological drug resistance denotes the
stage during which the cells are afflicted with a variety of
cellular stress signals and become more susceptible to the
type of damage likely to be inflicted by chemotherapeutic
drugs. Physiological drug resistance is characterized by
uncontrolled proliferation; impairment of apoptosis;
ability to repair DNA damage; and increasingly lower sen-
sitivity to chemotherapeutic drugs and/or radiation. Thus,
cells in this group are distinct from normal cells. Subse-
quent to chemotherapy, depending on its effectiveness,
multi drug resistance tumor cells evolve within the tumor
burden. After several courses of therapy, due to several
contributing factors, the host is overwhelmed with pre-
dominantly multi drug-resistant cells (referred to as path-
ologically drug resistant tumor cells) which, in turn,
confer unresponsiveness to chemotherapeutic agents and/
or adjuvant therapeutic treatment, leading to mortality.
Figures 2, 3 and 4 summarize the hypothesis advanced
here; they depict the scheme of events following chemo-
therapeutic treatment and the significance of the two dis-




A fundamental characteristic of malignancy is genetic
instability, which leads to a heterogeneous cell popula-
tion endowed with altered morphologies, invasiveness,
drug resistance and neovascularization, properties
acquired through genetic mutation and aberrant gene
expression. In addition, chemosensitivity is most likely
caused by genetic changes; it is an acquired feature that
appears at one specific stage and may be lost as the tumor
burden progresses. It is hypothesized that tumor cells
progress through two distinct stages, namely 'physiologi-
cal drug resistance' and 'pathological drug resistance'.
Subsequent to chemotherapy, the tumor cells are in a state
in which drug sensitivity is similar to that in the corre-
sponding normal cells. Within the tumor burden,
depending on their drug sensitivity, a more limited
number of tumor cells than corresponding normal cells
are damaged by chemotherapeutic agents.
As shown in Figure 2, following chemotherapy, the cells
are subjected to oxidative stress, which has been shown to
induce and sustain genomic and mitochondrial DNA
damage. Notwithstanding the mechanisms for repairing
such DNA damage, the loss of genomic DNA integrity,
entailing the down-regulation of apoptotic suppressor
proteins, drug-resistance suppressor proteins or cell cycle
regulatory proteins, obviously programs the cells to
undergo cell cycle arrest, culminating in apoptosis.
Tumor cells capable of repairing DNA damage but retain-
ing the upregulation of cell cycle regulatory proteins and
drug-resistance proteins are likely to survive both oxida-
tive stress and apoptosis [12,13]. It is speculated that this
defined sub-population is likely to represent the initially
drug-resistant cells, where the phenomenon is referred as
"physiological drug resistance".
It is also possible that a select population of tumor cells
may retain drug resistance and increase the expression of
pro-apoptotic genes while losing the cell cycle regulatory
protein(s). Such cells would be likely to undergo apopto-
sis. Thus, the evolving tumor would most likely contain a
defined population of cells tolerant of oxidative stress and
toxic drug effects, and also capable of bypassing apopto-
sis. Therefore, this initial phase is an exclusion phase during
which tumor cells that have lost cell cycle control and tumor
suppressor proteins are excluded from the rest of the tumor bur-
den as an evolving population endowed with physiological drug
resistance.
However, this selection process does not ensure that the
entire physiologically drug resistant fraction of the tumor
burden has become resistant to all drugs (Figure 2). To
support my argument that two distinct form of tumor cells
progress and lead to drug resistance mediated failure of
therapy, I invoke the process of "apomixis" [14] to erect a
hypothesis that depends on the presence of two hypotheti-
cal types of cell in the same somatic tissue (tumor burden)
and a potential exchange of genetic material between
them. "Apomixis" is a process that accounts for asexualre-
production in higher forms of life where sexual reproduc-
tion is the norm. In essence, the successful evolution of
pathologically drug-resistant cells may or may not follow
a pattern. The foremost factors determining the success of
this process are cellular genetic defects (mutations), and
the amount of chemotherapy and/or radiation the patient
will subsequently undergo. Together, these factorsTheoretical Biology and Medical Modelling 2005, 2:17 http://www.tbiomed.com/content/2/1/17
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determine or influence either the physiologically or the
pathologically drug resistant cells. In successive genera-
tions, resistant cells are likely to adopt at least one addi-
tional molecular mechanism for mounting an effective
defense against adjuvant therapy, after the initial radia-
tion or chemotherapy has failed, plausibly because of
apomixis.
Phase II. Tolerance
Tumor cells that are not susceptible to the toxic effects of
chemotherapeutic drugs and are tolerant of oxidative
stress are expected to possess one or more molecular
mechanisms to protect and maintain the proteins essen-
tial for survival. Such tumor cell populations show physi-
ological drug resistance. The sustained cytotoxic effects of
chemotherapeutic drugs would be likely neither to induce
genomic instability nor to affect cell cycle progression in
such a population. Also, insufficient exposure to the ther-
apy would leave a defined fraction of the tumor cells to re-
grow with the property of physiological drug resistance
and remain in the tumor burden. In addition to these
physiological possibilities, it seems reasonable to propose
that expression of several cell cycle regulatory proteins
will be lost and that cell cycle arrest will become dissoci-
ated from DNA damage. In turn, accumulated DNA dam-
age and uncontrolled cell cycle progression with impaired
apoptotic pathways will confer increased resistance to
chemotherapeutic drugs and/or adjuvant therapeutic
treatment, protecting against cell death and sustaining
tumor cell proliferation.
Phase I: Evolution of physiologically drug resistant cells by "exclusion" from chemotherapy-sensitive tumor cells Figure 2
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Therefore, this subpopulation of tumor cells is selected to
progress towards pathological drug resistance with or
without a specific escape mechanism for multiple drugs
(e.g. increased glutathione levels and altered DNA repair,
loss of cell cycle check point kinases). Also, it suggested
that pathological drug resistance probably represents a
stage during which resistance to various cytotoxic insults
increases markedly. It is also speculated that these distinct
tumor cell populations would probably coexist in a tumor
burden by "tolerating" each other (Figure 3).
A mechanistic working hypothesis is presented in Figure
3, in which physiological drug resistance progresses to
increased insensitivity to multiple drugs and subsequently
to multi drug resistance. With subsequent tumor progres-
sion, several defense mechanisms may be lost, including
dissociation of cell cycle arrest from DNA damage. Fur-
ther, clonal progression of the 'pathologically drug resist-
ant' cells may emerge as a result of drug-specific escape
mechanisms and the impairment of both triggering and
effectors mechanisms of apoptosis. Essentially, failure of
all options in a clinical chemotherapeutic regimen pro-
duces a shift from physiological drug resistance to patho-
logical drug resistance. Advanced clinical stages,
representing the failure of multiple episodes of a thera-
peutic regimen, would be more likely to contain patho-
logically drug-resistant cells that are beyond the
chemosensitive window.
Phase II: Existence of multiple mechanism(s) in a tumor burden for efficient evolution of pathologically drug resistant cells and  "toleration" of coexisting physiologically drug resistant tumor cells Figure 3
Phase II: Existence of multiple mechanism(s) in a tumor burden for efficient evolution of pathologically drug resistant cells and 
"toleration" of coexisting physiologically drug resistant tumor cells.
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Overall, it is still a strong possibility that both physiolog-
ically and pathologically drug-resistant cells, together
with yet unknown drug-sensitive cells, might coexist in a
tumor burden, complicating any viable alternative
approach to therapy. The promise of any therapeutic
measure at this point would largely depend on the prop-
erties of the predominantly surviving cell population in
the tumor burden. Regrettably, this would mean that the
cancer patient is losing ground in therapy and reaching
the clinical endpoint, which is not yet conclusive at this
point of the treatment.
Do the pathologically drug resistant tumor cells secrete some
unidentified factor(s) or adopt a novel mechanism(s) to trans-
form physiologically drug resistant tumor cells to pathologically
drug resistant ones? It has been suggested that such a "phase
transition" is a strong possibility [15].
Phase III. Progression
As shown in Figure 4, should the pathologically drug
resistant tumor cells overwhelm the tumor burden, with
or without the concomitant presence of physiologically
drug resistant cells, it is likely that the relapse may lead
towards complete failure of any remaining therapy.
Relapses in cases of metastatic tumor burdens cause dete-
rioration of the clinical scenario; metastatic tumors are
more aggressive, in particular with a pathologically drug-
resistant tumor burden. Progression of pathologically
drug-resistant cells would most likely occur because of
clonal dominance under the selection pressure imparted
Phase III: Progression of pathologically drug resistant tumor cells leading to mortality Figure 4
Phase III: Progression of pathologically drug resistant tumor cells leading to mortality.
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by the chemotherapy. In summary, a tumor burden that
already contains more pathologically resistant cells would
make the most intensive therapeutic regimen a futile exer-
cise. since the pathologically resistant tumor cells would
be insensitive as well as resistant to all forms of therapy.
At this point it is reasonable to conclude that the cancer
patient has reached the end point, meaning mortality.
Conclusion
In this hypothesis, I have considered the multiple mecha-
nism(s) of selection and proliferation in a distinct tumor
cell population, namely pathologically drug resistant
tumor cells, in the tumor burden, leading to the total fail-
ure of chemotherapy or an adjuvant therapeutic regimen.
Furthermore, the following four characteristic properties
of tumor cells may determine the pattern of drug resist-
ance: 1. Absence of contact inhibition/uncontrolled pro-
liferation; 2. Absence of apoptotic/necrotic mechanisms;
3. Multifactorial (epigenetic) up-regulation of drug resist-
ance genes; 4. Sustained oxidative stress-mediated dysreg-
ulation of metabolic pathways. All the aforesaid factors
would be likely to play pivotal roles in a developmental
stage-specific manner, but not all at once. Delineating the
specific molecular determinants conferring physiological
versus pathological drug resistance genotype/phenotypes
would be essential for providing an effective measure to
attenuate the impact of multi drug resistance and clinical
failure of the current therapeutic regimen.
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